Helporal

Helporal is an intravenous formulation of the analgesic paracetamol, supplied as a prescription‑only product in the European market. It contains paracetamol as the sole active ingredient and is administered directly into the bloodstream, allowing rapid reduction of pain and fever. Helporal is classified under the ATC code N02BE01 and works by inhibiting central prostaglandin synthesis. It is intended for use under medical supervision in clinical settings.

Helporal is indicated for the short‑term management of mild to moderate pain and for the reduction of fever when oral administration is not feasible or when a rapid onset of action is required.

- Acute postoperative pain - Pain associated with trauma or injury - Fever in hospitalized patients - Pain relief during surgical procedures - Management of pain in patients unable to take oral medication - Fever associated with infectious diseases when rapid antipyretic effect is desired. It may be used in emergency departments, intensive care units, and perioperative settings.

The safety profile of intravenous paracetamol, such as Helporal, reflects the known effects of paracetamol administered by other routes, with most reactions being mild and transient.

Common: - Mild nausea or upset stomach - Transient headache - Slight dizziness - Temporary flushing or warmth at the infusion site - Mild injection site discomfort - Temporary feeling of warmth - Transient mild itching

Serious: - Signs of severe allergic reaction such as rash, itching, swelling, or difficulty breathing - Elevated liver enzymes indicating possible hepatic stress - Unexplained low blood pressure during infusion - Rare cases of blood disorders such as thrombocytopenia - Signs of renal impairment such as reduced urine output - Severe skin reactions like Stevens-Johnson syndrome

When using Helporal, healthcare professionals should consider several precautionary measures to ensure patient safety and optimal therapeutic outcome.

- Assess liver function before initiating therapy, especially in patients with known hepatic disease. - Use the lowest effective dose and limit duration of treatment to reduce risk of toxicity. - Monitor vital signs during infusion, particularly blood pressure and heart rate. - Avoid use in patients with known hypersensitivity to paracetamol or its excipients. - Exercise caution in patients with renal impairment or dehydration. - Consider potential effects on fetal development; use only when benefit outweighs risk. - Review concomitant medications that may increase hepatic load.

Helporal may interact with other medicines; recognizing potential interactions helps prevent reduced efficacy or increased adverse effects.

Avoid: - Other paracetamol‑containing products, to prevent cumulative overdose. - Strong enzyme inducers such as rifampicin, which may lower paracetamol plasma levels. - High‑dose alcohol consumption, which can increase hepatic toxicity. - Combination with high‑dose aspirin, which may increase risk of renal impairment. - Combination with phenobarbital, a potent enzyme inducer, which can reduce therapeutic effect.

Use with caution: - Anticoagulants (e.g., warfarin) – monitor coagulation parameters. - Hepatotoxic drugs (e.g., isoniazid, valproic acid) – assess liver function. - Certain anticonvulsants (e.g., carbamazepine) – may affect metabolism. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may increase risk of gastrointestinal bleeding.